Medical Cannabis for Osteoarthritis — Switzerland 2026

Osteoarthritis is the most common joint disease in Switzerland. Cannabinoids reduce inflammation and pain — much cheaper for members.

Osteoarthritis (mostly knee, hip, hand) affects over 1 million people in Switzerland. Long-term NSAIDs carry cardiovascular and GI risk. CBD is anti-inflammatory, THC micro-doses improve sleep and pain threshold. Hunter 2018 (RCT) & Frane 2022 (registry, n=428): significant pain and function improvement. CannabisClub members: 50 CHF flat instead of 190.

What the studies show

Hunter 2018 (phase II RCT, knee OA): synthetic CBD reduced WOMAC pain significantly.

Frane 2022 (registry, n=428, 6 months): CBD-based preparations — 83 % pain reduction, 66 % less opioid and NSAID use.

Preparations & dosing

CBD oil 25–75 mg twice daily as anti-inflammatory base.

Topical CBD balm (5–10 %) 2–3× daily on hand/knee — evidence Frane 2022.

Save as a CannabisClub member

Rheumatology and pain clinics charge 190–250 CHF for cannabis consult. Members: 50 CHF flat, telemedicine possible. Registration free.

FAQ

Does cannabis replace my ibuprofen?

Can strongly reduce NSAID need (Frane 2022: -66 %). Switch only with physician — especially useful for cardio-renal risk patients.

What does membership save?

50 CHF instead of 190 CHF per consultation. Registration free.

Does insurance cover it?

In activated OA with chronic pain, increasingly possible via art. 71a — we check at first consultation.

Cannabis for Osteoarthritis — Prescription Switzerland 2026 (Members 50 CHF)